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Background
Although sudden death is a leading cause of mortality in
patients with sarcoidosis, cardiac involvement is often
unrecognized clinically. Delayed enhancement cardiovas-
cular magnetic resonance (DE-CMR) has been shown to
detect cardiac involvement in patients with sarcoidosis.
We sought to evaluate the prognostic value of myocar-
dial sarcoid involvement by DE-CMR.
Methods
Consecutive patients with biopsy proven extracardiac
sarcoidosis or suspected isolated cardiac sarcoidosis
were prospectively recruited. Patients with history of
cardiac surgery, heart transplant, documented coronary
artery disease, congenital heart disease were excluded.
Of the 251 meeting criteria, 231 participants were
enrolled (18 declined consent, 2 were minors) under-
went CMR, and followed for 2.7±2.2 years for major
adverse cardiac events (cardiac death, appropriate defi-
brillator shock, pacemaker placement, or heart trans-
plantation). CMR images were analyzed by a consensus
of two experienced readers who where blinded to all
other data.
Results
Patients were predominantly middle-aged (48±11 years),
female (63%), and African-American (72%). More than
half (53%) were on corticosteroid therapy at the time of
CMR. Lung (87%) and lymph nodes (45%) were the
most common organs of sarcoid involvement. On chest
radiography, most were pulmonary stage I /II (66%).
Overall, left ventricular ejection fraction (EF) was pre-
served (58 ±13%). Right ventricular EF was also
preserved (49% ±11%). Myocardial involvement (hyper-
enhancement) on DE-CMR was found in 60 patients
(26%). Most (80%, 48/60) had involvement of the inter-
ventricular septum. On follow-up, 16 patients had 19
cardiac adverse events, including 6 cardiac deaths, 2
heart transplants, 7 appropriate shocks, and 4 pace-
maker implantations for high grade AV block. Patients
with myocardial involvement by DE-CMR had a signifi-
cantly higher rate of adverse cardiac events than patients
without (Figure 1). On multivariable Cox analysis
including baseline clinical variables and left ventricular
EF, the presence of myocardial involvement was the
only independent predictor of cardiac events (HR 14.5;
95% CI 4.1, 50.8).
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In patients with sarcoidosis, myocardial involvement by
DE-CMR is the strongest independent predictor of
adverse cardiac prognosis.
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